ArticleFrontiers in oncology2026
Constructing and validating a prognostic prediction nomogram model for hepatocellular carcinoma patients following high-intensity focused ultrasound treatment.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop and validate a nomogram model based on biological information and conventional imaging indicators for predicting overall survival (OS) in patients with hepatocellular carcinoma (HCC) following high-intensity focused ultrasound (HIFU) treatment. Methods: This retrospective study included 407 patients with HCC who received HIFU treatment at the Second Affiliated Hospital of Chongqing Medical University between January 1, 2013, and June 30, 2024. Patients were randomly divided into a training cohort (n = 244) and a validation cohort (n = 163) at a ratio of 6:4. In the training cohort, univariate and multivariate Cox regression analyses were performed to identify independent predictors of OS. A nomogram was subsequently constructed to predict 1, 3, and 5-year survival rates. The predictive performance of the model was evaluated by assessing the concordance index (C-index), area under the receiver operating characteristic curve (AUC), calibration curves, and decision curve analysis (DCA). Kaplan-Meier survival curves were plotted to compare survival between high-risk and low-risk groups stratified by the nomogram, thereby validating the model's ability for clinical risk stratification. Results: Univariate Cox regression analysis identified 15 factors significantly associated with OS. Multivariate Cox analysis further determined that lymphocyte count, maximum tumor diameter, alpha fetoprotein level, number of tumor lesions, and portal vein invasion were independent risk factors. In the training cohort, the model exhibited a C index of 0.783. The AUCs for 1, 3, and 5-year survival were 0.814, 0.895, and 0.825, respectively. Calibration curves for 1, 3, and 5-year survival showed close agreement between the nomogram-predicted probabilities (0.835, 0.587, 0.40) and the observed survival rates (0.843, 0.586, 0.551), indicating excellent consistency. In the validation cohort, the C-index was 0.701, and the AUCs were 0.778, 0.679, and 0.754, respectively. The calibration curves also demonstrated good agreement between predicted and observed survival rates, reflecting acceptable consistency. In comparison, the 8th edition AJCC staging system yielded C indices below 0.68 in both cohorts, and its calibration curves showed suboptimal fit. Conclusion: The nomogram model developed in this study can effectively predict the OS rates in HCC patients following HIFU treatment, potentially improving therapeutic strategies and promoting personalized treatment approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.